Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Congress Materials Hero

Congress Materials

Congress material NephrologyIgAN

PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 mo vs >12 mo From Kidney Biopsy

Learn more

MA-SP-25-0214 | November 2025

Congress material NephrologyFSGS

Estimating the Benefits of Proteinuria Reduction on Kidney Failure Risk in the DUPLEX Study Using an Aligned FSGS Cohort From the UK RaDaR Registry

Learn more

MA-SP-25-0211 | November 2025

Congress material NephrologyFSGS

Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)

Learn more

MA-SP-25-0054 | April 2026

Explore our congress materials

Encore posters are re-presentations of previously published data.

Filter by:

Year

Year

×
Clear All

Event

Event

×
Clear All

Therapeutic area

Therapeutic area

×
Clear All

Disease area

Disease area

×
Clear All

Product

Product

×
Clear All

Study/Registry

Study/Registry

×
Clear All

Resource type

Resource type

×
Clear All
Clear All

Filter by:

Year

Year

×
Clear All

Event

Event

×
Clear All

Therapeutic area

Therapeutic area

×
Clear All

Disease area

Disease area

×
Clear All

Product

Product

×
Clear All

Study/Registry

Study/Registry

×
Clear All

Resource type

Resource type

×
Clear All

Results145

Sort by

Poster NephrologyIgAN

SPARX and SPARTAN Cohort B: Trials in Progress Evaluating Sparsentan for Recurrent or De Novo Focal Segmental Glomerulosclerosis (FSGS) and Immunoglobulin A Nephropathy (IgAN) Following Kidney Transplant

American Transplant Congress (ATC) – 2026

Learn more
Presentation NephrologyFSGS

 Antiproteinuric Effect of Sparsentanin Focal Segmental Glomerulosclerosis (FSGS) in the Ongoing 156-Week DUPLEX Open-Label Extension (OLE)

63rd European Renal Association (ERA) Congress – 2026

Learn more
Summary NephrologyFSGS

In DUPLEX, Patients With Focal Segmental Glomerulosclerosis (FSGS) Reached Low Proteinuria More Often With Sparsentan vs. Irbesartan Regardless of Baseline Proteinuria

National Kidney Foundation (NKF) Spring Clinical Meetings – 2026

Learn more
Summary NephrologyFSGS

Antiproteinuric Effect of Sparsentan After Maximized Irbesartan in Patients With Focal Segmental Glomerulosclerosis (FSGS) in the DUPLEX Open-Label Extension (OLE)

National Kidney Foundation (NKF) Spring Clinical Meetings – 2026

Learn more
Poster NephrologyIgAN

Use of Implementation Science to Optimize Management of Rare Kidney Disease

National Kidney Foundation (NKF) Spring Clinical Meetings – 2026

Learn more
Poster NephrologyIgAN

Proteinuria Reductions With Sparsentan (SPAR) Combined With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN): A Single Site Case Series

National Kidney Foundation (NKF) Spring Clinical Meetings – 2026

Learn more
Load more
MSL CTA Image

Connect with our MSL team today

Arrange a meeting with a member of our medical science liaison (MSL) team to discuss the latest insights, clinical trial data, and management trends.

Find your MSL